KIT and maculopapular cutaneous mastocytosis: The results of this phase 1 dose-escalation/expansion study demonstrated that potent and selective inhibition of KIT D816V by avapritinib elicited rapid, profound reductions of measures of mast cell disease burden, resolved organ damage, and improved patients’ symptoms across the spectrum of AdvSM subtypes.